The pharmacologic target for colistin is an average steady-state plasma concentration of 2 mg/L (Css,avg)
The susceptibility breakpoint for colistin for Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter is less than or equal to 2 mg/L
Colistin doses in the scientific literature may be expressed in different ways. The conversion is as follows:
All doses for Colistin should be expressed in Colistin Base Activity